Lopressor: Difference between revisions
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
{| style="border: 3px solid #696969;" | {| style="border: 3px solid #696969;" | ||
| style="background: #000000; border: 0px; padding: | | style="background: #000000; border: 0px; padding: 20px 20px; width: 800px;" | | ||
<center> | <center> | ||
<font color="#F8F8FF">'''WARNING'''</font> | <font color="#F8F8FF">'''WARNING'''</font> | ||
| Line 19: | Line 17: | ||
Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered Lopressor, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1-2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, Lopressor administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue Lopressor therapy abruptly even in patients treated only for hypertension. | Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered Lopressor, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1-2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, Lopressor administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue Lopressor therapy abruptly even in patients treated only for hypertension. | ||
</font></b> | </font></b> | ||
|} | |} | ||
Revision as of 08:23, 13 March 2014
 | |
| Clinical data | |
|---|---|
| Trade names | Lopressor, Toprol-xl |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682864 |
| [[Regulation of therapeutic goods |Template:Engvar data]] |
|
| Pregnancy category | |
| Routes of administration | Oral, IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 12% |
| Metabolism | Hepatic via CYP2D6, CYP3A4 |
| Elimination half-life | 3-7 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C15H25NO3 |
| Molar mass | 267.364 g/mol |
| 3D model (JSmol) | |
| Melting point | 120 °C (248 °F) |
| |
| |
| (verify) | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
WARNING See full prescribing information for complete boxed warning.
|